Amring Pharmaceuticals Inc. Announces the Approval and Launch of Generic Isoproterenol Hydrochloride Injection USP
Amring Pharmaceuticals Inc. (Amring), a niche generic and brand pharmaceutical company, announced today that it has received FDA approval for generic Isoproterenol Hydrochloride USP, (0.2 mg/mL) available as 1 mL or 5 mL Single-Dose Vials, (AP rated generic equivalent of Isuprel), and has immediately begun commercialization activity.